CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, ...

Though CAR T cells have been effective against certain blood cancers, they have not been for solid tumors. Now, a new form of ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

A proof-of-concept study opens up an avenue for treating solid tumours that express low levels of a target antigen.

It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...

Pre-wired ability in ‘resting’ T cells to remember past viral foes discovered, a promising breakthrough for targeted cancer therapies. A team of immunologists at the University of Massachusetts ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...